The top 10 drug sales companies in China's hospital market announced that they are favored by purchasing
-
Last Update: 2019-10-23
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
[pharmaceutical network industry trends] according to data, in 2018, the total sales volume of China's hospital drug market has reached 771.8 billion yuan, with an annual growth rate of 3.3% The growth rate is the same as last year The driving factors of market growth include the expansion of the coverage of medical insurance, the enhancement of patients' self medication awareness, the improvement of medical infrastructure and accessibility, innovation and the listing of new products, etc With the continuous growth of the total sales volume of the hospital drug market, what pharmaceutical companies can occupy the market share of the hospital's use of whole drugs? Recently, the China Pharmaceutical Association released the 2018 annual monitoring report on hospital medication (chemical and biological products), which ranked the top 10 pharmaceutical manufacturers in terms of purchasing amount in 2018, with Pfizer, AstraZeneca, Hengrui pharmaceutical, Yangzijiang pharmaceutical, Sanofi, Roche, Bayer, Qilu pharmaceutical, Novartis and Zhengda Tianqing on the list Among them, AstraZeneca, Hengrui pharmaceutical, Sanofi, Roche and Bayer are the enterprises whose purchasing amount has increased by more than 10% year on year Next, the author focuses on the top five enterprises Pfizer: purchase amount accounts for 3.75% In 2018, Pfizer, as a pharmaceutical giant, was more happy than worried about new drug research and development as a whole Especially in terms of the approval dynamics of FDA and EMA, Pfizer became one of the winners in the pharmaceutical industry in 2018, adding new impetus to its revenue growth after the expiration of its core drugs such as atorvastatin and pregabalin AstraZeneca: procurement accounts for 3.01% of the total In 2018, AstraZeneca's annual revenue in the Chinese market reached 3.795 billion US dollars (more than 25 billion yuan), an increase of 28% compared with 2.955 billion US dollars in 2017, and its proportion in the total revenue further increased from 13.2% in 2017 to 17.2% Among them, the tumor business revenue expanded rapidly to $6.028 billion with a growth rate of 50%, becoming the core business of AstraZeneca at present In the later stage, with the expansion and marketing of a series of new drugs in China, AstraZeneca's revenue in China will reach a new high Hengrui medicine: as a leading enterprise in the domestic pharmaceutical industry, the purchase amount accounts for 2.79% The main products of Hengrui medicine cover anti-tumor drugs, surgical anesthesia drugs, special infusion, contrast agents, cardiovascular drugs and many other fields, especially the tumor, anesthesia and contrast agents maintain a rapid growth in 2018 and after 13 varieties, such as cyclophosphamide, atracurium besylate and docetaxel, were approved by FDA of the United States During the reporting period, the operating revenue of overseas market reached 651 million yuan, up 2.24% year on year At present, the company has rich reserves of research varieties and R & D investment is in the forefront of domestic pharmaceutical industry Yangtze River Pharmaceutical Industry: the purchasing amount accounts for 2.62% of the total In the past year, Yangtze River Pharmaceutical industry has made fruitful achievements in R & D and innovation, obtained 10 production approvals for chemical drugs and traditional Chinese medicine, 2 innovative drugs have entered clinical research, 5 varieties have achieved import substitution through the consistency evaluation of quality and efficacy of generic drugs, and the development potential has been further enhanced In 2019, Mecobalamin tablets, meloxicam tablets and cefradine capsules have been evaluated successively in the consistency evaluation, and will occupy more shares in the hospital market in the future Sanofi: the purchasing amount accounts for 2.46% of the total In 2018, Sanofi, a French pharmaceutical giant, covered diabetes, cardio cerebrovascular, mature products and professional care in China and emerging markets, with sales of 7.05 billion euros (7.95 billion US dollars), an increase rate of 9.3% In particular, after the outbreak of the vaccine incident in China last year, pentaxim ®, Sanofi's quintuple vaccine, resumed supply, which led to a 2.4% year-on-year increase in the performance of Sanofi Pasteur, a vaccine business unit, and a 3% increase in consumer health sales.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.